Bufalin disrupts the ATP1A1-Cav-1 complex, reversing drug resistance in melanoma (63), while cardiac glycosides inhibit STAT1-mediated IDO1 expression (60), demonstrating synergy with immune checkpoint inhibitors. The gene discussed is CAV1; the disease is melanoma.